Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
3-Year Clinical Outcomes After Implantation of Permanent-Polymer Versus Polymer-Free Stent: ReCre8 Landmark Analysis.
van Hemert ND, Voskuil M, Rozemeijer R, Stein M, Frambach P, Pereira B, Rittersma SZ, Kraaijeveld AO, Leenders GEH, Timmers L, van der Harst P, Agostoni P, Stella PR; ReCre8 Study Investigators. van Hemert ND, et al. Among authors: rozemeijer r. JACC Cardiovasc Interv. 2021 Nov 22;14(22):2477-2486. doi: 10.1016/j.jcin.2021.08.078. JACC Cardiovasc Interv. 2021. PMID: 34794654 Free article. Clinical Trial.
Rationale and design of amphilimus sirolimus-eluting stents versus zotarolimus-eluting stents in all-comers requiring percutaneous coronary intervention (ReCre8): A multicenter randomized clinical trial.
Rozemeijer R, Stein M, Frambach P, Voskuil M, Kraaijeveld AO, Rodríguez-Olivares R, Timmers L, Pereira B, Rittersma SZ, Agostoni P, Doevendans PA, Stella PR. Rozemeijer R, et al. Catheter Cardiovasc Interv. 2018 Feb 15;91(3):410-416. doi: 10.1002/ccd.27142. Epub 2017 May 22. Catheter Cardiovasc Interv. 2018. PMID: 28544782
Clinical outcomes of complex real-world diabetic patients treated with amphilimus sirolimus-eluting stents or zotarolimus-eluting stents: A single-center registry.
Rozemeijer R, Benedetto D, Kraaijeveld AO, Voskuil M, Stein M, Timmers L, Rittersma SZ, Agostoni P, Doevendans PA, Stella PR. Rozemeijer R, et al. Cardiovasc Revasc Med. 2018 Jul;19(5 Pt A):521-525. doi: 10.1016/j.carrev.2017.10.011. Epub 2017 Oct 26. Cardiovasc Revasc Med. 2018. PMID: 29137966
Randomized All-Comers Evaluation of a Permanent Polymer Zotarolimus-Eluting Stent Versus a Polymer-Free Amphilimus-Eluting Stent.
Rozemeijer R, Stein M, Voskuil M, van den Bor R, Frambach P, Pereira B, Koudstaal S, Leenders GE, Timmers L, Rittersma SZ, Kraaijeveld AO, Agostoni P, Roes KC, Doevendans PA, Stella PR; ReCre8 Study Investigators. Rozemeijer R, et al. Circulation. 2019 Jan 2;139(1):67-77. doi: 10.1161/CIRCULATIONAHA.118.037707. Circulation. 2019. PMID: 30586704 Clinical Trial.
One-year clinical outcomes of patients treated with polymer-free amphilimus-eluting stents or zotarolimus-eluting stents: A propensity-score adjusted analysis.
Rozemeijer R, van Muiden IG, Koudstaal S, Leenders GE, Timmers L, Rittersma SZ, Kraaijeveld AO, Doevendans PA, Voskuil M, Stella PR. Rozemeijer R, et al. Catheter Cardiovasc Interv. 2019 Jul 1;94(1):61-69. doi: 10.1002/ccd.28041. Epub 2019 Jan 2. Catheter Cardiovasc Interv. 2019. PMID: 30604493 Free PMC article.
Patient-tailored antithrombotic therapy following percutaneous coronary intervention.
van der Sangen NMR, Rozemeijer R, Chan Pin Yin DRPP, Valgimigli M, Windecker S, James SK, Buccheri S, Ten Berg JM, Henriques JPS, Voskuil M, Kikkert WJ. van der Sangen NMR, et al. Among authors: rozemeijer r. Eur Heart J. 2021 Mar 7;42(10):1038-1046. doi: 10.1093/eurheartj/ehaa1097. Eur Heart J. 2021. PMID: 33515031 Free PMC article. Review.
15 results